Generate Biomedicines, founded by Flagship Pioneering, uses generative AI to design entirely new protein therapeutics across modalities, advancing a pipeline of AI-generated drug candidates.
Company Profile
CEO
Mike Nally
Founded
2018
HQ
Somerville, MA
IPO Status
private
Fundraising Status
private
Secondary Market
Implied price / share
$5.75
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.